← Back to Clinical Trials
Recruiting NCT06448390

NCT06448390 Exercise Training Study of Patients With Claudicatio Intermittens

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06448390
Status Recruiting
Phase
Sponsor Norwegian University of Science and Technology
Condition Claudication, Intermittent
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-01-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Physical training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-01-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the study is to evaluate whether walking capacity in patients with intermittent claudication is improved more by home-based 5+ exercise training than by current recommendations of daily walking.

Eligibility Criteria

Inclusion Criteria: 1. Pain in the calves after 300 m, or less measured on a treadmill 2. Stable symptoms last 6 months or more 3. The pain must be gone within 5 minutes after the patients stop walking 4. Ankle-Brachial index at 0.7 or lower at rest 5. Using statins and antiplatelet drugs since at least 3 months 6. age\> 18 years 7. Signed consent Exclusion Criteria: 1. pain in the hips or elsewhere outside the calves while walking 2. Remaining pain more than 5 minutes after stopped walking. 3. Impossible to compress the arteries while measruing ABI or ABI lower than 0.4 4. Use of statins and antiplatelet drugs less than 3 months 5. symptoms less than 6 months 6. Diabetes measured with HbA1c being over 48 mmol/mol (6%) 7. Revascularisation the last 6 months 8. Pain in the calves after longer than 300 m measured on a treadmill 9. Reduced mobility in the ankles 10. Reduced physical ability to perform a test on a treadmill. 11. Age less than 18 years 12. General conditions that impairs the ability to take part in a training study including Obesity, KOLS, heart disease, arthrosis, inflammatory joint diseases . 13. No Signed consent

Contact & Investigator

Central Contact

Erney Mattsson, Professor

✉ erney.mattsson@gmail.com

📞 0046737854490

Principal Investigator

Joakim Nordanstig, Professor

PRINCIPAL INVESTIGATOR

Sahlgrenska University Hospital

Frequently Asked Questions

Who can join the NCT06448390 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Claudication, Intermittent. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06448390 currently recruiting?

Yes, NCT06448390 is actively recruiting participants. Contact the research team at erney.mattsson@gmail.com for enrollment information.

Where is the NCT06448390 trial being conducted?

This trial is being conducted at Ålesund, Norway, Bergen, Norway, Drammen, Norway, Grålum, Norway and 10 additional locations.

Who is sponsoring the NCT06448390 clinical trial?

NCT06448390 is sponsored by Norwegian University of Science and Technology. The principal investigator is Joakim Nordanstig, Professor at Sahlgrenska University Hospital. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology